NANTKWEST INC. DL-,0001 Forum: Community User: Ibt2

38,70$ go to the moon 🌙

38,10$ + 17,27% 🌋🌋🌋

Da kann sie doch komfortabel übernachten, bis wir die 40$ angehen. 😎

36,36$

Zukaufen bei 22€ (nicht der Tiefpunkt aber ok) hat sich schon gelohnt.

Jawoll danke 👀

Aktueller Kurs 35,94$ +10,62% 🌋🌋🌋

Hab dem Support geschrieben, damit es hier auch voran geht!

Danke Lirum

Umstellung kann etwas dauern, das ist normal.

Bei Ecograf hatte ich nach dem KE 3 Tage, bevor ich was in meinem Broker sehen konnte

Lirum: ich Handel Nantkwest über Scalable Capital. Und heute wird ja nichts angezeigt. Ist das normal?

Vorhin 2 mal kurz die 36$ Marke durchbrochen. Stehen aktuell bei 35$ +7,8%

Ohne Nanktwest macht es in meinem Depot kein Spaß. Ist die größte Position bei mir. Broker zeigt nur von gestern den letzten Stand an -.- Dachte es sollte heute Nachmittag weitergehen... :)

https://twitter.com/nantkwest/status/1369665299381768193?s=21

ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company MARCH 10, 2021 CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 10, 2021-- ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker. ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.” The company’s broad-based platforms are based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells. ImmunityBio has a broad immunotherapy clinical pipeline of over 40 clinical trials in Phase I, II and III development across 19 indications in solid and liquid cancers and infectious diseases. The clinical-stage pipeline and intellectual property portfolio spans 17 first-in-human antibody cytokine fusion proteins, chemo immuno-modulators, vaccine vectors, and cell therapies in 25 Phase II and III clinical trials. Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). ImmunityBio is a leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise, ready-to-scale facilities, extensive and seasoned R&D, clinical trial, and regulatory operations and development teams.